# Parkinson’s Disease: Conventional Pharmacotherapy, Drug Delivery Innovations, and Emerging Therapeutic Targets

## TL;DR

This review discusses Parkinson’s disease, its treatment with current drugs, innovations in drug delivery, and new therapeutic targets for future therapies.

## Contribution

The paper provides a comprehensive overview of PD pharmacotherapy, delivery innovations, and emerging targets for future research.

## Key findings

- Current PD treatments like levodopa are limited by motor fluctuations and side effects.
- New drug delivery methods aim to improve efficacy and convenience for patients.
- Emerging therapeutic targets are being explored to address PD's underlying pathology.

## Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms (bradykinesia, rigidity, resting tremor) and a wide range of non-motor features. The core pathological process is degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to striatal dopamine deficiency, while additional neurotransmitter systems contribute to non-motor symptoms. PD is a common age-related disorder; global estimates for 2019 indicate that more than 8.5 million people were living with PD, and prevalence increases steeply with age. Current pharmacological therapy is mainly symptomatic and is centered on levodopa and other dopaminergic strategies, but treatment response can be limited by motor fluctuations, dyskinesia, and adverse effects. Therefore, formulation and delivery innovations (e.g., dispersible preparations, intestinal gel, and continuous infusion approaches) aim to stabilize drug exposure and improve convenience, especially in patients with swallowing difficulties or advanced disease. This review summarizes conventional drug classes and their dosage forms, highlights formulation-driven strategies to improve efficacy and tolerability, and outlines emerging pathways and targets being explored for future therapies.